Health Economics and Outcomes Research Services Market

What is the Health Economics and Outcomes Research Services Market forecast to be worth by 2036?

USD 2.8 billion in 2026 to USD 7.9 billion by 2036 at 10.9% CAGR.

• The Health Economics and Outcomes Research Services market reached USD 2.5 billion in 2025 as sponsors planned evidence needs before launch and reimbursement review.
• Demand is forecast to increase from USD 2.8 billion in 2026 to USD 7.9 billion by 2036.
• The market is projected to expand at a CAGR of 10.9% from 2026 to 2036.

What are the defining numbers behind Health Economics and Outcomes Research Services Market growth?

USD 5.1 billion absolute opportunity by 2036.

• Demand Drivers in the Market
  • Payer review is expected to raise demand for economic evidence that explains why clinical benefit deserves reimbursement support. In January 2026, the Centers for Medicare & Medicaid Services selected 15 high-cost Medicare Part B and Part D drugs for the third negotiation cycle; those drugs were used by about 1.8 million Medicare beneficiaries from November 2024 to October 2025 and accounted for about USD 27 billion in Medicare spending.
  • Pharmaceutical sponsors need earlier evidence planning because launch teams must prepare cost-effectiveness models before pricing discussions begin. The Organisation for Economic Co-operation and Development reported in 2025 that OECD countries spent 9.3% of GDP on health in 2024, keeping launch evidence tied to value-for-money questions.
  • Real-world evidence programs are anticipated to support more HEOR work when sponsors compare treatment value after clinical trials close.
  • Digital evidence tools are expected to shorten review cycles when research teams screen studies and test model assumptions.
• Key Segments Analyzed
  • By Service Offering: Health Economics Studies is expected to hold 39.0% share in 2026 because payer-facing evidence remains the core buyer requirement.
  • By Application: Cost-effectiveness Analysis is projected to account for 36.0% share in 2026 as reimbursement teams compare therapy value with care costs.
  • By End User: Pharmaceutical Companies are anticipated to capture 41.0% share in 2026 given their need for launch evidence and pricing support.
  • By Delivery Model: Project-based Services is estimated to represent 48.0% share in 2026 due to study-specific budgets and defined reimbursement milestones.
  • By Research Methodology: Decision Analytic Modeling is forecast to hold 44.0% share in 2026 because HTA submissions require model-based comparisons.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Senior Consultant at Fact.MR, states, “Health economics and outcomes research is moving closer to launch strategy because payers want value evidence before price discussions mature. Sponsors that connect clinical endpoints with budget impact and local reimbursement rules are expected to protect access more effectively than teams that treat HEOR as late-stage documentation.”
• Strategic Implications
  • Sponsors should begin HEOR planning before pivotal trial readouts so economic endpoints support launch and reimbursement work.
  • Service providers can improve selection chances by combining literature review with economic modeling inside one payer evidence workflow.
  • Pharmaceutical teams should align HEOR vendors with market access groups because payer questions often shape the final evidence package.
  • Investors should separate providers with direct HEOR capability from wider clinical outsourcing firms that support adjacent evidence needs.

The USA leads at 11.8% CAGR through payer review depth. Germany follows at 11.4% as health technology assessment discipline supports structured submissions. The UK reaches 10.9% through national reimbursement review. Canada records 10.5% through public payer scrutiny. France posts 10.0%. Japan reaches 9.6%, and Australia records 9.2%.

How does the Health Economics and Outcomes Research Services Market break down by segment?

Health Economics Studies leads Service Offering at 39.0% share in 2026. Cost-effectiveness Analysis leads Application at 36.0% share in 2026.

Why does Health Economics Studies lead Service Offering?

Health Economics Studies is projected to account for 39.0% share in 2026.

This service area leads because reimbursement decisions require evidence on value and affordability. Healthcare business intelligence work reinforces the need for clean evidence views before pricing decisions.

Why does Cost-effectiveness Analysis lead Application?

Cost-effectiveness Analysis is expected to hold 36.0% share in 2026.

Payers use this application to compare therapy value with existing care costs before coverage decisions are made. It fits value-based healthcare service models where reimbursement depends on measurable outcomes.

Why do Pharmaceutical Companies lead End User?

Pharmaceutical Companies are anticipated to account for 41.0% share in 2026.

Pharmaceutical sponsors carry the largest evidence burden because they need payer dossiers and access arguments before launch. The pharmaceuticals portfolio keeps this buyer group central to HEOR service spending. EMA's 2025 annual report shows that the agency recommended 104 medicines for marketing authorisation in 2025, including 38 with new active substances, giving pharmaceutical sponsors a steady need for access evidence after approval.

Why do Project-based Services lead Delivery Model?

Project-based Services is estimated to represent 48.0% share in 2026.

Sponsors often commission HEOR work around a therapy or reimbursement milestone. Geography can shape the same project when local payer rules change the evidence package. Biopharmaceutical contract research organization work when buyers need specialist support without permanent staff.

Why does Decision Analytic Modeling lead Research Methodology?

Decision Analytic Modeling is forecast to capture 44.0% share in 2026.

Modeling is used when reimbursement decisions need structured comparisons of treatment pathways and cost consequences. It can draw on clinical trial management system inputs when trial evidence must support economic models.

What is accelerating Health Economics and Outcomes Research Services Market adoption, and what is holding it back?

Demand is expected to rise as payers ask for clearer evidence on value and budget impact. Growth is likely to face limits where data access is uneven. Model transparency and payer requirements vary by country.

Drivers Impact Analysis

• Payer evidence requirements: Coverage teams are expected to request clearer proof that therapy benefits justify reimbursement and budget impact.
• Launch-stage value planning: Sponsors are anticipated to start HEOR work earlier when pricing and market access teams prepare payer dossiers.
• Real-world evidence use: Post-trial data is expected to support stronger value arguments where clinical outcomes must be observed in routine care.

Opportunity Impact Analysis

• AI-assisted evidence synthesis: Research teams are expected to use digital tools to screen studies faster and improve review consistency.
• Local payer dossier adaptation: Providers with country-specific reimbursement knowledge are expected to gain more work from global launch teams.
• RWE model updates: Sponsors are likely to refresh economic models when routine-care outcomes change the payer evidence base.

Restraints Impact Analysis

• Data access limits: HEOR projects are expected to slow when claims data and registries are difficult to access. Patient-reported outcomes can add collection barriers.
• Model transparency concerns: Payers are expected to challenge submissions when assumptions are unclear or sensitivity testing is weak.
• Country-specific payer rules: Service providers need local reimbursement knowledge before they adapt one evidence package across several markets.

Which countries are scaling Health Economics and Outcomes Research Services Market fastest?

• The country comparison spans 2.6 percentage points and forms three practical growth bands across the forecast period.
• The USA remains 0.4 percentage point above Germany through payer review depth and advanced evidence requirements.
• Germany remains 0.5 percentage point above the UK because structured health technology assessment supports formal evidence submissions.
• The UK remains 0.4 percentage point above Canada through national reimbursement review and clinical evidence assessment.
• Canada remains 0.5 percentage point above France as public payer scrutiny supports demand for economic evidence.
• France remains 0.4 percentage point above Japan through reimbursement controls and payer-facing value review.
• Japan remains 0.4 percentage point above Australia as aging-related care needs increase the value of outcomes evidence.

Comparable CAGRs can create different entry conditions because payer rules differ by country. HTA processes and sponsor evidence budgets shape local entry conditions. Full report coverage includes North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa.

What supports USA adoption?

11.8% CAGR, supported by payer review depth and advanced evidence requirements.

Large payer networks make the USA a demand center for HEOR services. Sponsors need budget-impact arguments before broad coverage decisions progress. Vendors that can explain value in payer language are expected to have an advantage. CMS also reported that 2024 U.S. health spending equaled USD 15,474 per person and 18.0% of GDP.

How is Germany scaling demand?

11.4% CAGR, backed by structured health technology assessment and formal evidence submissions.

Germany’s growth is tied to reimbursement review that places weight on comparative evidence and economic reasoning. Local adaptation matters because a global value model rarely answers every payer question without country-specific assumptions.

What is driving UK growth from 2026 to 2036?

10.9% CAGR, supported by national reimbursement review and clinical evidence assessment.

The UK requires clear cost-effectiveness reasoning before many access decisions mature. Sponsors therefore need economic models that fit national review expectations and explain where a therapy improves outcomes at an acceptable cost.

How is Canada developing demand?

10.5% CAGR, supported by public payer scrutiny and pharmaceutical evidence planning.

Canada’s growth reflects payer reviews that examine clinical value and affordability across public plans. Pharmaceutical companies need submissions that translate trial outcomes into budget terms for local access decisions.

How does France perform?

10.0% CAGR, led by reimbursement controls and payer-facing value review.

France requires evidence that can compare new therapies with established treatment pathways. HEOR vendors support sponsors by adapting outcomes and cost assumptions to the country’s access review environment.

What supports Japan’s growth?

9.6% CAGR, backed by aging-related care needs and demand for outcomes evidence.

Japan’s growth reflects the need to connect clinical evidence with care-cost pressure across mature healthcare settings. Sponsors require local interpretation before pricing and reimbursement reviews progress.

What supports Australia’s growth?

9.2% CAGR, supported by evidence-led access decisions and structured reimbursement review.

Australia’s market favors clear clinical and economic reasoning before access decisions advance. HEOR services are expected to support submissions that balance patient outcomes with payer affordability

Who leads the Health Economics and Outcomes Research Services Market?

IQVIA Holdings Inc. and ICON plc show the clearest direct relevance across HEOR and access support. Syneos Health, Inc. and Parexel International Corporation add real-world evidence and modeling depth. RTI Health Solutions and Oracle Corporation (Oracle Life Sciences) extend the provider field through research services and analytics. Costello Medical and Axtria Inc. add specialist evidence and payer strategy depth.

The competitive field is service-led. Providers compete on analyst depth and payer familiarity. Model quality and local evidence adaptation remain selection factors. Providers tied to digital transformation in healthcare are expected to gain value when they turn fragmented clinical data into payer-ready evidence. In June 2025, IQVIA launched custom AI agents built with NVIDIA technology to support life sciences workflows such as literature review, market assessment, and commercial launch work. In October 2025, Syneos Health and CareMetx announced a patient access partnership that connects CareMetx technology with Syneos Health's Kinetic platform to address access challenges and reduce time to therapy.

Which companies are the key providers?

Key companies include IQVIA Holdings Inc.; ICON plc; Syneos Health, Inc.; Parexel International Corporation; Cytel Inc.; RTI Health Solutions; Oracle Corporation (Oracle Life Sciences); Costello Medical; Axtria Inc.

• IQVIA Holdings Inc.
• ICON plc
• Syneos Health, Inc.
• Parexel International Corporation
• Cytel Inc.
• RTI Health Solutions
• Oracle Corporation (Oracle Life Sciences)
• Costello Medical
• Axtria Inc.

Bibliography

• Centers for Medicare & Medicaid Services. (2026, June 24). NHE fact sheet.
• Centers for Medicare & Medicaid Services. (2026, January 27). CMS announces selection of drugs for third cycle of Medicare Drug Price Negotiation Program, including first-ever Part B drugs.
• Organisation for Economic Co-operation and Development. (2025, November 13). Healthcare quality improving, but financial pressures rise.
• National Institute for Health and Care Excellence. (2025, July 7). NICE annual report and accounts: 2024 to 2025.
• European Medicines Agency. (2026, June 11). 2025 annual report of the European Medicines Agency.
• Canadian Institute for Health Information. (2025, November 27). NHEX trends, 2025 — Snapshot.
• IQVIA. (2025, June 11). IQVIA launches new AI agents for life sciences and healthcare.
• CareMetx. (2025, October 21). CareMetx and Syneos Health unite to accelerate patient access.

This Report Answers

• The report provides strategic intelligence on service and application choices that shape payer evidence planning.
• Segment analysis covers Health Economics Studies and Cost-effectiveness Analysis as the share leaders within the 2026 market.
• Country outlook evaluates the USA and Germany alongside the UK and Canada. France, Japan and Australia complete the growth comparison.
• Competitive analysis profiles the listed HEOR service providers without assigning company share estimates.
• Evidence workflow assessment covers decision analytic modeling and project-based delivery.

What does the Health Economics and Outcomes Research Services Market cover?

Health economics and outcomes research services evaluate the economic and humanistic value of healthcare interventions. The work supports payer review and reimbursement evidence when access decisions require structured analysis.

The Health Economics and Outcomes Research Services Market covers outsourced research work used by sponsors and healthcare organizations. It includes economic studies and payer evidence. Value dossiers and real-world evidence support are included when outcomes measurement supports value assessment. Accountable care solutions are included where payer contracts require outcomes measurement.

What is included in the scope?

HEOR services used by pharmaceutical companies and related healthcare buyers are included when they support access decisions.

The scope includes Service Offering and Application. End User and Delivery Model are included. Research Methodology is included where it supports HEOR evidence generation. Regional coverage includes developed payer markets and emerging healthcare systems where sponsor evidence needs are expanding.

What is excluded from the scope?

General consulting without HEOR evidence output remains outside the scope of this market.

The scope excludes unrelated management consulting and general clinical trial execution. Pure medical writing without economic or outcomes analysis is outside scope. Standalone data software is excluded unless it directly supports HEOR service delivery.

How Was the Analysis Built?

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 interviews.

• Primary Research: Interviews with manufacturers, retailers, salon operators, and experts examine purchase priorities, adoption, approval requirements, and competitive positioning.
• Desk Research: Desk research covers government statistics, regulatory publications, company filings, trade data, technical studies, industry associations, standards, and public policy.
• Market Sizing and Forecasting: Estimates combine historical performance, demand indicators, pricing, segment shares, company participation, country growth, adoption patterns, and barriers to expansion.
• Data Validation and Update Cycle: Findings are validated against public data, company activity, regulatory changes, product launches, recalls, and adoption shifts.